Navigation Links
Clinical Proficiency Testing Programs

ProductsClinical Proficiency Testing Programs
Company American Proficiency Institute
Item Clinical Proficiency Testing Programs
Features 
Description American Proficiency Institute offers innovative proficiency testing solutions with outstanding customer service and technical support. As a result, API is one of the largest proficiency testing providers in the world with over 12,000 laboratories enrolled.

Here are just some of the advantages of using API:

  • Paperless Proficiency Testing
  • Free CME/CMLE Credits Sponsored By ASCP
  • Rapid Turnaround Time
  • Management Reports
  • Large Peer Groups
Info American Proficiency Institute
Customer Service: (800) 333-0958
Web site: http://www.api-pt.com/

Related medicine products :

1. Clinical DataBase
2. Freedom EVO Clinical
3. OLA2500 Clinical Lab Automation System
4. OLA4000 Clinical Lab Automation System
5. Aeroset Clinical Chemistry System
6. Express Plus Clinical Chemistry Analyzer
7. i-STAT Portable Clinical Analyzer
8. HAI CL-1000xyzClinical Specular Microscope
9. UniCel DxC 600 Synchron Clinical System
10. Clinical Information System
11. The Clinical Reference Laboratories at National Jewish Medical and Research Center
Straight shafts with extra fine pointed tips and 6mm tying platform. Smooth handle with dull finish/
A necessary addition to any Trial Lens set, the Reichert Trial Frame provides a comfortable fit and smooth controls for quick, easy lens fitting.,The robust design, high-quality materials, and p
... of the most competitively priced chair and stand ...odern ergonomic design, contemporary styling, or t...Advantage manual recline chair meets the needs of ... in patient comfort and ease of use. The counterba...
...ombines the traditional features you would expect,...ion and cord-free battery power.,The cool-run... clear green illumination target, and virtually ma...d completely cordless, the ML1 Manual Lensometer g...
Medicine Products:
(Date:5/16/2008)... report side effects, but critics want agency to a...ealthDay News) -- Direct-to-consumer drug ads on t...that would allow consumers to report adverse side ..., The experts serve on a panel that advises the U....s are already mandated by the FDA for print ads. A...
(Date:5/16/2008)...eing presented at the American Society of Clinical... change treatment practice in about 25 percent of ...oposed changes to the way colorectal cancers will ...ncer Institute (NCI) SEER population-based statist...nical trial data, shows that outcomes of patients ...
(Date:5/16/2008)...s located just beneath the lining of the uterus (s...ial cavity after uterine artery embolization (UAE)...ding to a new study. , The study included 49 pa...ination before and after UAE. The study found that...ed to the endometrial cavity after UAE, said Sachi...
(Date:5/16/2008)... Cast Scheduled for May 19 at 10:15 a.m. Eastern T...esponse Biomedical,Corporation (TSX: RBM, OTCBB: R...cutive Officer, is scheduled to present at the Rod...nce on Monday May 19th at 10:15 a.m.,EDT., A live... the Company,s,Web site at, http://www.responsebio...
Breaking Medicine News(10 mins):Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
... expression of therapeutic genes, which will have ... presented today at the 10th Annual Meeting of the...e. Carefully regulating gene expression is crucia...erapy. For many applications, gene transfer is bei...
...nts with obstructive sleep apnea (OSA) have higher... from the lining (endothelium) of their blood vess...ho do not have OSA. The finding may help explain w... for cardiovascular disease (CVD). According to t...
...ulin gene to diabetes patients using nanoparticles...of the American Society of Gene Therapy (ASGT) in ... autoimmune destruction of the insulin producing p...e loss of insulin, blood sugar levels rise too hig...
...n could help treat people who are suffering from s...g to traditional treatment. Thomas Schlaepfer, pr...ity Hospital in Bonn, Germany and associate profes...at Johns Hopkins University School of Medicine in ...
Other Medicine News:Health News:New Platform for Regulating Expression of Therapeutic Genes Unveiled 2Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 2Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 3Health News:Novel Delivery Method of Insulin Gene to Combat Juvenile Diabetes Developed 2Health News:Implanting Electrodes in the Brain Could Help Treat Severe Depression 2
(Date:5/16/2008)...e/ -- Data from three studies,evaluating associati...vels,and the rate of blood transfusions, as well a...ment for erythropoiesis-stimulating agents (ESAs),... will be presented at the,American Society of Clin...th. The meeting will take place in Chicago from Ma...
(Date:5/16/2008)...PEGylation of a Small Molecule with ..., Calif., May 16 /- Nektar,...sults today from a Phase 1,study of NKTR- 102, PEG...-tumor activity in patients with refractory solid ...small molecule PEGylation technology,produced an i...
(Date:5/16/2008)...ay Offer Novel Approach to Blood .../- Pharmacopeia (Nasdaq:,PC... of novel small,molecule therapeutics, announced t... Receptor Antagonist (DARA), showed statistically ...a study in patients with mild to,moderate hyperten...
(Date:5/15/2008)...wire/ -- Eisai Corporation of North,America announ...acts about,compounds in the company,s oncology pip...research have been accepted for presentation at th...linical Oncology (ASCO),taking place in Chicago f...stracts on Eisai marketed products and,investigati...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Convera 28R 29 and Canon Communications Launch PharmaLiveSearch com 11492 1Convera 28R 29 and Canon Communications Launch PharmaLiveSearch com 11492 2Convera 28R 29 and Canon Communications Launch PharmaLiveSearch com 11492 3General Atlantic and Hellman 26 Friedman Purchase HLTH Corporations Remaining Interest in Emdeon 11489 1General Atlantic and Hellman 26 Friedman Purchase HLTH Corporations Remaining Interest in Emdeon 11489 2General Atlantic and Hellman 26 Friedman Purchase HLTH Corporations Remaining Interest in Emdeon 11489 3General Atlantic and Hellman 26 Friedman Purchase HLTH Corporations Remaining Interest in Emdeon 11489 4Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3177 1Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3177 2Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3177 3Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 1Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 2Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 3
...anespimycin Shown to Have No Effect on QTc Interva... Kosan,Biosciences Incorporated today presented sa... its lead Hsp90 inhibitor,tanespimycin (KOS-953)....ents was conducted in four Phase 1 trials of tanes...d in more than 85,patients. Tanespimycin was found...
...AWRENCEVILLE, N.J.--(BUSINESS WIRE)--Apr 16, 2007 ...presentation of several,scientific studies relatin...nnual Meeting of the American Association for Canc... Los Angeles,California. During this meeting, on ...ientific founder of Onconova was honored as,the re...
Other Medicine Technology:Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 2Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 3Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 4Onconova Therapeutics Announces Presentation of Clinical and,Non-Clinical Results for Its Lead Compound ON 01910.Na at American,Association of Cancer Research Conference in Los Angeles 2Onconova Therapeutics Announces Presentation of Clinical and,Non-Clinical Results for Its Lead Compound ON 01910.Na at American,Association of Cancer Research Conference in Los Angeles 3